Advanced Therapies Europe 2026

Advanced Therapies Europe 2026, an event organized by Phacilitate, will take place from September 7 to 9, 2026, in Barcelona, Spain.

The opportunity to participate in a key event that brings together European leaders in advanced therapies, as well as experts, developers, and regulators, to discuss the latest developments in the research, development, and commercialization of cellular, gene, and regenerative therapies should not be missed.

Advanced Therapies Europe provides a unique platform for collaboration, knowledge exchange, and the creation of synergies that drive the future of personalized and innovative medicine.

The topics of interest at Advanced Therapies Europe include biotechnology investment, focusing on opportunities for startups and investors, as well as women's leadership and inclusivity in the sector. Key discussions will cover the scaling and production of gene and cell therapies, particularly in AAV manufacturing, and the European regulations and regulatory challenges. Additionally, important topics such as patient access to treatments and the industrialization of cell therapies will be addressed, aiming to overcome barriers to their clinical implementation.

Whether you are launching a new therapy, seeking strategic partnerships, or aiming to anticipate regulatory and market changes, Advanced Therapies Europe is designed to provide you with practical insights and meaningful connections.

• Expand your network – Meet CEOs from biotechnology, pharmaceutical strategists, CDMO leaders, and investors who are shaping the next wave of therapeutic innovation.
• Gain strategic perspective – Access expert-led industry sessions on regulation, funding trends, scaling solutions, and commercial strategy.
• Discover what lies ahead – Explore the latest advances in cell and gene therapy platforms, biotechnological technologies, and regenerative medicine.

Companies and entities in the BioRegion of Catalonia can enjoy a 20% discount by using the code BIOCAT20 at the time of registration.

07/09/2026

09:15h - 09:55h | Theatre 1&2

What it takes to fund advanced therapies in 2026

• Artemy Shumskiy, Principal - LongeVC
• Gadareth Higgs, Partner - Advantary Capital Partners
• Laura Rodriguez, Partner - Invivo Partners
• Malgorzata Rogalska, Analyst - Ysios Capital
• Rahul Khetan, Venture Associate - UCB Ventures

09:55h - 10:35h | Theatre 1&2

Panel: Alternative funding models and capital structures for biotech

• Angel Lucio, CEO - TETRANEURON
• Claudio Santos, CEO - Gyala Therapeutics
• Kiren Baines Mortimore, CEO & Co-Founder - Valaya Bio
• Michael Meyers, Vice Chairman, Head of M&A and Strategic Advisory Services - HC Wainwright & Co

11:05h - 11:45h | Theatre 1&2

Differentiation or bust: How to stand out in a saturated market

• Faizzan Ahmed, Managing Partner - YZR Capital Biotech
• Ana Duran, Associate - LifeLink Ventures
• Jose Mesa, Partner - Columbus Venture Partners
• Marc Ramis Castelltort, Founder & Managing Partner - Montana
• Matt Symes, Investor - Delin Ventures

11:45h - 12:15h | Theatre 1&2

Fireside Chat: What “investment ready” looks like in 2026

• Avencia Sanchez-Mejias, CEO & Co-Founder - Integra Therapeutics

• Luis Pareras, Managing Partner - Invivo Partners

   

13:40h - 14:10h | Workshop Room

Fireside chat: We’ve heard the challenges. Now, what are we changing?

• Ingrid Marchal-Gerez, Director, EMEA Cell Therapy Commercial Operations - Johnson & Johnson
• Lynette James, VP Supply Chain & External Manufacturing - Quell Therapeutics
• Montse Daban, Director of Strategic Foresight and International Relations - Biocat
• Vasiliki Kalodimou, Assistant Professor - European University Cyprus

15:15h - 16:15h | Workshop Room

Roundtable: The power of community: Building your industry network

• Margot Pont, VP Translational Development - Integra Therapeutics

15:15h - 16:15h | Theatre 1&2

Roundtable: Non-linear career paths: Leveraging unique journeys

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra

   

08/09/2026

09:15h - 09:50h | Theatre 1&2

Europe’s ATMP rulebook reset: The 12-month pathway from fragmented rules to trusted EU execution

• Esteve Trias, ATMP Expert
• Jacob George, Chief Medical & Scientific Officer - MHRA
• Robert Allen, Chief Business Officer - Dark Horse Consulting

• Sean Russell, Head of Regulatory Affairs – Fondazione Telethon

   

9:50h - 10:30h | Theatre 1&2

Panel: Europe’s Roadmap Winning the Next Wave of ATMP R&D: What Europe must resolve to compete on speed, scale and return

• Bo Wiinberg, CBO - Novo Nordisk Foundation Cellerator
• Jacqueline Barry, Chief Clinical Officer – Cell and Gene Therapy Catapult
• Jim Lund, Chief Business Development Officer - CCRM Nordic
• Miguel Forte, CEO - Kiji Therapeutics
• Montse Daban, Director of Strategic Foresight and International Relations - Biocat
• Paolo Morgese, Vice President Public Affairs, Europe - Alliance for Regenerative Medicine

12:15h - 12:45h | Theatre 1

CGT clinical trials at pace: What’s accelerating, what’s stuck and how Europe turns trials into treatments

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra
• Joana Claverol, Head of Clinical Research Unit - Sant Joan de Deu
• Manel Juan Otero, Head of Immunology - Hospital Clínic de Barcelona
• Sean Russell, Head of Regulatory Affairs - Fondazione Telethon

13:00h - 14:00h | Workshop Room

Panel: Designing advanced therapies that survive scale: from early decisions to commercial readiness

• Emmanuelle Cameau, Scientific Director Genomic Medicine - Cytiva
• Esteve Trias, ATMP Expert
• Margot Pont, VP Translational Development - Integra Therapeutics
• Núria Gavaldà, ATMP Platform Director - Banc de Sang i Teixits (Blood and Tissue Bank)

15:00h - 15:15h | Theatre 1

Spotlight: A new lentiviral vector for in vivo CAR-T with high specificity and efficacy for multi-immune cell targeting

• Stefanos Theoharis, CEO - OneChain Immunotherapeutics

   

15:15h - 16:00h | Theatre 1

Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?

• Andrew Frazer, Associate Director, Scientific Solutions - Rose BioSolutions
• Margot Pont, VP Translational Development - Integra Therapeutics
• Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
• Stefanos Theoharis, CEO - OneChain Immunotherapeutics

15:30h - 16:00h | Theatre 2

Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems

• Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
• Esteve Trias, ATMP Expert
• Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
• Tamara Loos, Consultant - ENIMAXE

16:30h - 17:30h | Workshop Room

When venture philanthropy meets venture creation 

• Gonzalo Fernandez-Miranda, Co-founder & CEO - CureAge Therapeutics

   

16:30h - 17:30h | Workshop Room

Roundtable: Cracking the EU Code: Turning regulatory & supply complexities into a smooth process

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra

   

16:30h - 17:30h | Workshop Room

Roundtable: Managing immunogenicity risk across the next generation of advanced therapies

• Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals

   

09/09/2026

09:00h - 10:30h |  Theatre 1

Innovation Exchange

• Gadareth Higgs, Partner - Advantary Capital Partners
• Malgorzata Rogalska, Analyst - Ysios Capital
• Matt Symes, Investor - Delin Ventures

• Rahul Khetan, Venture Associate - UCB Ventures

   

10:30h - 11:15h |  Theatre 1

Designing CGTs in the age of agentic AI: How to accelerate discovery and development without losing regulatory control

• Aneta Tyszkiewicz, Director Data Digital - EFPIA - European Federation of Pharmaceutical Industries and Associations
• Clara Cuervo, Head of AI and Digital Transformation Cell Therapy Clinical Operations Global - AstraZeneca
• Domitille Halie, Head of Scientific Project Management - WhiteLab Genomics
• Marc Guell, Cofounder & Scientific Head - Integra Therapeutics
• Vasiliki Kalodimou, Assistant Professor - European University Cyprus

12:15h - 12:30h |  Theatre 1

Spotlight: A first-in-class CAR-T cell therapy for HER2 resistant solid tumors

• Judit Anido, Business Lead - EraCell

   

12:30h - 12:45h |  Theatre 1

Spotlight: Public–private partnership models that combine academic, clinical, and industry strengths to accelerate translation of advanced therapies

• Simon de Miquel, Strategic Project Manager & Business Developer - Advanced Therapies - Barcelona Children's Hospital Sant Joan de Deu

   

12:45h - 13:30h |  Theatre 1

Panel: Access is the real innovation: How Europe turns breakthroughs into therapies patients can actually receive

• Alessandra Magnani, Head of Advanced Therapies and Immunotherapy Platform - Hospital Sant Joan de Déu 
• Ingrid Marchal-Gerez, Director, EMEA Cell Therapy Commercial Operations - Johnson & Johnson
• Marion Hitchcock, Managing Director Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager - Bayer
• Mark Flower, VP of Business Development, Cell and Gene Technologies - AGC Biologics

• Sonja Steppan - Fresenius Group

   

13:30h - 14:30h |  Workshop Room

From Early Development to Commercial Readiness: Real-World Lessons in Advancing Lentiviral-Based Therapies

• Miguel Forte, CEO - Kiji Therapeutics
• Natalia Elizalde - VIVEbiotech

• Willem-Jan Krebber, Chief Development Officer - Genewity Holding B.V

   

15:25h - 16:05h |  Theatre 1

Panel: Modalities and markets at the crossroads - Where advanced therapies go next and how Europe chooses to compete

• Bernd Eschgfäller, Board Member - T-CURX
• Carolina Pola, CEO - STAb Therapeutics
• Khalid Shah, Director, Center of Stem Cell and Translational Immunotherapy - Brigham and Women's Hospital
• Ricardo Baptista, CTO - SmartCella

• Robert Fabregat Fuentes, CEO - Biocat

   

On July 15 at 2 pm, Advanced Therapies Europe organised the webinar “Europe’s ATMP Roadmap: From Strategy to Execution in a New Global Reality”, a pre-event session to discuss Europe’s challenges in innovation, manufacturing and clinical trials in advanced therapies.

Montse Daban, Director of Strategy and Global Partnerships at Biocat, took part alongside Miguel Forte, CEO of Kiji Therapeutics, and Paolo Morgese, VP Public Affairs Europe at the Alliance for Regenerative Medicine.